PURPOSE: The survival of patients with hepatocellular carcinoma (HCC) has been prolonged with improvements in various diagnostic tools and treatment modalities. Consequently, bone metastases from HCC are diagnosed more frequently. We investigated the clinical features, prognosis, treatment outcomes, and prognostic factors of HCC presenting with bone metastasis. METHODS: Between June 2000 and April 2007, we recruited 37 consecutive HCC patients presenting with bone metastasis. These patients were divided into an untreated control group (n = 16) and a treated group (n = 21). RESULTS: The mean age of the patients was 61.1 years (male:female, 31:6). The most common cause of HCC was hepatitis B virus infection (56.8%). Twenty-two patients (59.5%) were of Child-Pugh class A and 15 (40.5%) were of Child-Pugh class B. Spinal metastasis was most common and noted in 21 patients (56.7%). The treatment modalities in the treated group included intra-arterial chemotherapy in nine patients (42.8%), systemic chemotherapy in five (23.8%), and both intra-arterial and systemic chemotherapy in seven (33.4%). The median survival of all patients was 6.2 months (range 0.7-46.6); that of untreated control group and the treated group was 2.9 (range 0.7-42.2) and 9.7 (range 0.9-46.6) months, respectively, with no significant difference (log-rank test, P = 0.081). Cox regression analysis revealed that the presence of ascites at the initial presentation was the only prognostic factor (P = 0.016). CONCLUSION: Although our study showed that locoregional and/or systemic chemotherapy did not provide significant survival prolongation compared to supportive care in patients with HCC initially accompanied by bone metastasis, a more large-scaled randomized study might be required.
PURPOSE: The survival of patients with hepatocellular carcinoma (HCC) has been prolonged with improvements in various diagnostic tools and treatment modalities. Consequently, bone metastases from HCC are diagnosed more frequently. We investigated the clinical features, prognosis, treatment outcomes, and prognostic factors of HCC presenting with bone metastasis. METHODS: Between June 2000 and April 2007, we recruited 37 consecutive HCC patients presenting with bone metastasis. These patients were divided into an untreated control group (n = 16) and a treated group (n = 21). RESULTS: The mean age of the patients was 61.1 years (male:female, 31:6). The most common cause of HCC was hepatitis B virus infection (56.8%). Twenty-two patients (59.5%) were of Child-Pugh class A and 15 (40.5%) were of Child-Pugh class B. Spinal metastasis was most common and noted in 21 patients (56.7%). The treatment modalities in the treated group included intra-arterial chemotherapy in nine patients (42.8%), systemic chemotherapy in five (23.8%), and both intra-arterial and systemic chemotherapy in seven (33.4%). The median survival of all patients was 6.2 months (range 0.7-46.6); that of untreated control group and the treated group was 2.9 (range 0.7-42.2) and 9.7 (range 0.9-46.6) months, respectively, with no significant difference (log-rank test, P = 0.081). Cox regression analysis revealed that the presence of ascites at the initial presentation was the only prognostic factor (P = 0.016). CONCLUSION: Although our study showed that locoregional and/or systemic chemotherapy did not provide significant survival prolongation compared to supportive care in patients with HCC initially accompanied by bone metastasis, a more large-scaled randomized study might be required.
Authors: Sang Hoon Ahn; Kwang Hyub Han; Jeong Youp Park; Young Hoon Youn; Chang Mo Moon; Kwan Sik Lee; Chae Yoon Chon; Young Myoung Moon; Do Yun Lee; Jong Tae Lee Journal: Yonsei Med J Date: 2004-10-31 Impact factor: 2.759
Authors: Jong In Yang; Jung Mook Kang; Hee Jin Byun; Go Eun Chung; Jeong Yoon Yim; Min Jung Park; Jeong Hoon Lee; Jung Hwan Yoon; Hyo Suk Lee Journal: Korean J Hepatol Date: 2011-12
Authors: N Poddar; R Ramlal; S Ravulapati; S M Devlin; S Gadani; C I Vidal; D Cao; A S Befeler; J Lai Journal: Curr Oncol Date: 2017-08-31 Impact factor: 3.677
Authors: Kyu Sik Jung; Kyeong Hye Park; Young Eun Chon; Sa Ra Lee; Young Nyun Park; Do Yun Lee; Jin Sil Seong; Jun Yong Park Journal: Korean J Hepatol Date: 2012-03-22
Authors: C Rory Goodwin; Vijay Yanamadala; Alejandro Ruiz-Valls; Nancy Abu-Bonsrah; Ganesh Shankar; Eric W Sankey; Christine Boone; Michelle J Clarke; Mark Bilsky; Ilya Laufer; Charles Fisher; John H Shin; Daniel M Sciubba Journal: World Neurosurg Date: 2016-05-13 Impact factor: 2.104
Authors: Yong Kang Lee; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang Hun Lee; Do Yun Lee; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park Journal: BMC Cancer Date: 2013-01-03 Impact factor: 4.430